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Abstract — The main areas of the research at the Blood Transfusion Center of 
Slovenia are cell therapies, stem cells and new diagnostic reagents, based on 
monoclonal antibodies (mAbs). Our laboratories are equipped for cell-culture 
work (certified GLP; GMP in reconstruction), molecular biology, immunological 
techniques and biochemistry. In the course of our research we conducted 
studies and applied projects (the last mainly industrial) beside production of 
reagents, with common topic - the antibodies. They were prepared and used 
to optimise and validate ELISA tests for quality control assessment of the 
end-product (polyclonal antibodies, in production of drugs), to study protein 
structure, for immunodiagnostics and as potential immunotherapeutics. Among 
different mAbs, which we produced in the last decade, a panel of mAbs against 
prion protein (PrP) and mAbs against bilitranslocase (prepared in collaboration 
with the University of Trieste) will be studied with different project partners in 
the scope of Trans2Care. We are fully dedicated to translate the results of the 
basic research onto applied, possibly clinical level and to contribute to improved 
healthcare in a sense of advanced modes of immunotherapeutics development 
and cell based therapies.
Index Terms — human prion protein, prion, bilitranslocase, monoclonal 
antibodies, immunodiagnostics, immunotherapy, stem cells, cell therapy 
———————————————————
1 INTRODUCTION
Blood Transfusion Centre of Slovenia (BTCS) is a national blood bank, responsible for the supply of safe blood and blood components in our country. Beside that, 
we are providing diagnostic and therapeutic services and blood-derived drugs to our 
hospitals. We are a strong partner of the University of Ljubljana, giving lectures and 
providing experimental work to students of graduate studies at Faculty of Medicine, 
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Faculty of Pharmacy, Faculty of Chemistry and Chemical Technology and Faculty 
of Health Sciences. We are also involved in postgraduate programs of Biomedicine 
and Biotechnology at the University of Ljubljana. The same personnel is engaged in 
research and development at BTCS, being members of three research groups: Tissue 
Typing Center, Transfusion Medicine and Biomedicine. As of 2004 BTCS has an ISO 
9001 standard and is a WHO Collaborating Center and an EFI (European Federation of 
Immunogenetics) member. 
2 RESEARCh AT ThE BTCS
Research activities at the BTCS started as early as 1953, when the institution was registered for the research and development in medical biotechnology and 
medical sciences. In the course of next four decades, activities in this field intensified, 
especially in the research. During last 15 years the three forementioned research 
groups, conducted 33 national research projects, 3 national programmes, 6 industrial 
projects and 6 international projects, financed by Slovene Research Agency, by 
Ministry for Higher Education, Science and Technology, by industrial partners as 
well as the European Comission. 18 young researchers/PhD students were trained 
at the BTCS in the scope of these projects, covering medicine, life sciences and 
biotechnology. Our development is closely related to our routine operations and 
services (blood collection and processing, blood grouping, cell therapeutical services) 
and assures constant education and follow-up in transfusion medicine. The main 
areas of our research are cell therapies, stem cells and new diagnostic reagents, based 
on monoclonal antibodies (mAbs). Our laboratories are equipped for cell-culture work 
(certified GLP; GMP in reconstruction), molecular biology, immunological techniques 
and biochemistry. On the basis of our research, we were invited to take part of the 
educational programmes at the University of Ljubljana (see introduction). 
2.1 Biomedicine research group 
Our research group evolved from the department for the producion of diagnostic reagents, in charge of production of diagnostic reagents for blood grouping under 
GMP (Good Manufacturing Practice) conditions. Our first research project included 
the production of potent mouse IgM monoclonal antibodies (mAbs) against AB0 blood 
group system in early ninetees of the last century, which were introduced into routine 
work in the form of diagnostic reagents, registered in 1998. In consequent years, we 
conducted research and applied projects (the last mainly for the industry) beside 
production of reagents, with common topic - the antibodies. They were prepared and 
used to optimise and validate ELISA tests for quality control assessment of the end-
product (polyclonal antibodies, in production of drugs), to study protein structure, for 
diagnostics and as potential therapeutics (mAbs). Among different mAbs, which we 
produced in the last decade, a panel of mAbs against prion protein (PrP) [1, 2, 4, 6, 9, 
10] and mAbs against bilitranslocase (prepared in collaboration with the University 
of Trieste, started in 2006) [11] will be studied with different project partners in the 
scope of Trans2Care. 
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3 CONTRIBUTION TO TRANS2CARE
3.1 Bilitranslocase 
Our current, ongoing collaboration with the T2C partners includes the research of mAbs against bilitranslocase in collaboration with University of Trieste (prof. S. 
Passamonti). This collaboration will further develop as we anticipate our first joint 
publications [11] .
Figure 1: ICC staining of HepG2 cells with anti-bilitranslocase mAb 6E4/1F2 (40x, 2.4s).
3.2 Prion diseases
In our research on prion diseases we constructed and tested a panel of mAbs against prion protein (PrP) enabling us to distinguish and differentiate between the wild type 
PrPc and its pathogenic form PrPSc, which is of a great diagnostic value in Creutzfeld 
Jacob’s disease (CJD). This research yielded EU and US patents for these antibodies 
as well as our common publications with T2C partners SISSA – prof. G. Legname and 
University of Trieste - prof. R. Gennaro [1, 6]. In the frame of T2C we are aiming at 
upgrading this collaboration in two possible directions: the use of proteomics for the 
identification of novel biomarkers of prion diseases using animal models of CJD as 
well as clinical samples of CJD. These biomarkers could help us elicit the molecular 
background of prion diseases as well as serve as potential diagnostic or therapeutic 
tools. 
Alternatively we aim at using the expertise and specialized infrastructure (GMP 
laboratory standards) of the BTCS in the field of cell based therapeutics to reaserch a 
potential of neural stem cell based therapies for prion diseases using animal models 
of CJD. 
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Figure 2: Immunohistochemistry of mAb V5B2 binding to the pathogenic form of PrPSc in CJD brain section, 
compared to normal brain section. (a) Diffuse PrPSc plaque depositions are visible in a synaptic section of 
cerebellum (40x). (b) PrPSc – negative staining of normal brain hypocampus (20x).
4 CONCLUSIONS
In the frame of T2C, we offer our above mentioned expertise to project partners, within the fields of development of immunotherapeutics, immunodiagnostics, cell based 
therapies and proteomics as well as whereever sinergies are anticipated. Thus far, we 
have proven our capacity of inter-regional collaborations and we are looking forward to 
expanding the ongoing and new collaborations with Slovene and Italian partners. We 
are fully dedicated to translate the results of the basic research onto applied, possibly 
clinical level and to contribute to improved healthcare in a sense of advanced modes of 
immunotherapeutics development and cell based therapies.
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